Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIUNITE-05: Neoadjuvant QL1706 + Chemoradiotherapy in Gastric Cancer
NCT07165847Phase 2Recruiting
- Start
- Jul 2025
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in gastric cancer (GC), gastroesophageal junction adenocarcinoma. Started Jul 2025; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07165847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07165847.